Intravenous Anti-CGRP Antibodies for Fast Migraine Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for migraine and headache disorders, particularly chronic migraine, do not provide immediate relief or effective prevention, and there is a need for more targeted therapies that address the role of Calcitonin Gene Related Peptide (CGRP) in these conditions.
Innovation Solution
Intravenous administration of anti-CGRP antibodies, specifically formulated with light and heavy chain CDR sequences, provides immediate relief and prevention of migraine or headache symptoms by targeting CGRP, with dosages of 100 or 300 mg administered every 10-14 weeks, typically every 12 weeks, in a formulation including histidine, sorbitol, and polysorbate 80.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional migraine treatments are used, then headache symptoms may be managed, but immediate relief and effective prevention are not achieved
Solution Approach 1:
The patent changes the target parameter from general migraine management to specific CGRP pathway inhibition. By designing antibodies that specifically bind to CGRP or its receptor, the treatment achieves immediate and reliable relief by directly blocking the neuropeptide responsible for migraine pathophysiology, rather than using conventional treatments that manage symptoms without immediate effect.
Solution Approach 2:
The patent introduces anti-CGRP antibodies as intermediary substances that mediate between the CGRP neuropeptide and the migraine pain pathway. These antibodies serve as molecular intermediaries that block CGRP from binding to its receptor, thereby interrupting the signaling pathway that causes migraine symptoms and enabling immediate relief.
2Reliability
If targeted anti-CGRP therapy is implemented, then immediate relief and prevention are achieved, but treatment frequency and formulation complexity increase
Solution Approach 1:
The patent segments the antibody molecule into functional components with specific CDR sequences designed to bind different CGRP isoforms. This segmentation allows the antibody to specifically target CGRP-alpha and CGRP-beta, achieving reliable prevention while maintaining a manageable administration protocol through standardized dosing intervals.
Solution Approach 2:
The anti-CGRP antibody formulation is designed to be multi-functional, providing both immediate relief during acute migraine attacks and prevention of future attacks. The same antibody preparation serves dual purposes, reducing the need for separate acute and preventive treatments and simplifying the overall therapy protocol.
3Manufacturing precision
If CGRP targeting therapy is used, then migraine pathophysiology is directly addressed, but manufacturing and formulation requirements become more stringent
Solution Approach 1:
The patent uses recombinant DNA technology to create copies of the anti-CGRP antibody gene in host cells. This allows for standardized production of the antibody protein with consistent CDR sequences that specifically target CGRP. The copying process enables precise manufacturing control while simplifying formulation production through standardized biopharmaceutical manufacturing protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-CGRP antibodies significantly alleviate headache and migraine symptoms within hours to days, reducing pain levels and frequency, and can prevent future occurrences, even in cases of medication overuse headache.
Implementation Method 1
specifically bind to human Calcitonin Gene Related Peptide (hereinafter 'CGRP')
Data Source
AI summary
Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.